Researchers have developed a novel monoclonal antibody (αFZD7-288.1) that specifically targets the Frizzled 7 receptor and significantly inhibits Wilms tumor growth in preclinical studies. This antibody disrupts canonical Wnt signaling by reducing active β-catenin levels and downregulating key target genes including C-MYC, AXIN2, and CCND1. In vivo xenograft studies demonstrated that αFZD7-288.1 treatment at 10 mg/kg significantly reduced tumor volumes with minimal toxicity compared to paclitaxel chemotherapy.
Related search suggestions: functions.RelatedSearchTerms("suggestions":["suggestion":"Wilms tumor staging COG vs SIOP","score":0.9,"suggestion":"Wilms tumor genetics WT1 WT2 IGF2","score":0.86,"suggestion":"treatment protocols vincristine actinomycin doxorubicin Wilms tumor","score":0.8])
Research into circulating tumor DNA (ctDNA) in blood and urine is ongoing. Liquid biopsies may soon allow clinicians to monitor treatment response, detect minimal residual disease, and catch relapses early without relying solely on repeated radiation-heavy imaging scans. Long-Term Survivorship Care wilms tumor ppt new
It represents the fourth most common pediatric cancer overall and the most common renal malignancy in children.
Recent findings show that children with stage I–II FAWT achieve with vincristine/dactinomycin/doxorubicin chemotherapy (DD4A) plus flank radiation, while children with stage IV disease benefited from intensified regimens. Related search suggestions: functions
Formulate a multimodal treatment plan based on stage and risk factors. Slide 3: Introduction & Epidemiology Most common pediatric renal cancer (~90%). Peak incidence: 2–3 years of age. Originates from the metanephric blastema. Most cases are unilateral and sporadic. Slide 4: Genetic Syndromes
Complete blood count (CBC), renal function tests, and urinalysis. The "Rule of 10s" (Classic Review): Bilateral. Unfavorable histology. Vascular invasion. Pulmonary metastases at presentation. 5. Staging and Histology (COG Guidelines) Recent findings show that children with stage I–II
Involves genomic imprinting disruption, particularly the loss of maternal imprinting of IGF2 and H19 .